Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.

ABSTRACT:

Background

The epidermal growth factor receptor (EGFR) inhibitors represent the first-line therapy regimen for non-small cell lung cancer (NSCLC). Most of these inhibitors target the ATP-site to stop the aggressive development of NSCLC. Stabilization of the ATP-binding on EGFR is difficult due to autophosphorylation of the EGFR domain. This leads to activation of nonintrinsic influence of the tumor microenvironment and expression of anti-apoptotic pathways and drug resistance.

Methods

The NSCLC related literature search was carried out using online databases such as Scopus, Web of Sciences, PubMed, Protein Data Bank and UniPort for the last ten years and selected articles are referred for discussion in this review.

Results

To overcome the problem of mutations in NSCLC

SUBMITTER: Maity S 

PROVIDER: S-EPMC7381467 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature